Corcept Therapeutics Inc (CORT) stock
CORTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 11/30328% above fair value
$64.98−2.81 (-4.15%)
Close on Nov 19, 2026Market cap $7.02BP/E 154.7Yield –
Corcept Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Corcept Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $830.81M, up 16.0% year over year. For fiscal 2025 it was $761.41M, up 12.8% from the year before. Over ten years it grew 31.2% a year on average. The highest annual figure on record is $761.41M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $761.41M | +12.8% |
| FY2024 | Dec 31, 2024 | $675.04M | +39.9% |
| FY2023 | Dec 31, 2023 | $482.38M | +20.0% |
| FY2022 | Dec 31, 2022 | $401.86M | +9.8% |
| FY2021 | Dec 31, 2021 | $365.98M | +3.4% |
| FY2020 | Dec 31, 2020 | $353.87M | +15.5% |
| FY2019 | Dec 31, 2019 | $306.49M | +22.0% |
| FY2018 | Dec 31, 2018 | $251.25M | +57.8% |
| FY2017 | Dec 31, 2017 | $159.20M | +95.8% |
| FY2016 | Dec 31, 2016 | $81.32M | +61.7% |
| FY2015 | Dec 31, 2015 | $50.29M | +89.4% |
| FY2014 | Dec 31, 2014 | $26.55M | +156.4% |
| FY2013 | Dec 31, 2013 | $10.36M | +213.2% |
| FY2012 | Dec 31, 2012 | $3.31M | +11303.4% |
| FY2009 | Dec 31, 2009 | $29.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $256.15M | +31.7% |
| Q1 FY2026 | Mar 31, 2026 | $164.90M | +4.9% |
| Q4 FY2025 | Dec 31, 2025 | $202.13M | +11.1% |
| Q3 FY2025 | Sep 30, 2025 | $207.64M | +13.7% |
| Q2 FY2025 | Jun 30, 2025 | $194.43M | +18.7% |
| Q1 FY2025 | Mar 31, 2025 | $157.21M | +7.1% |
| Q4 FY2024 | Dec 31, 2024 | $181.89M | +34.3% |
| Q3 FY2024 | Sep 30, 2024 | $182.55M | +47.7% |
| Q2 FY2024 | Jun 30, 2024 | $163.80M | +39.1% |
| Q1 FY2024 | Mar 31, 2024 | $146.81M | +39.0% |
| Q4 FY2023 | Dec 31, 2023 | $135.41M | +31.4% |
| Q3 FY2023 | Sep 30, 2023 | $123.60M | +21.5% |
| Q2 FY2023 | Jun 30, 2023 | $117.72M | +13.9% |
| Q1 FY2023 | Mar 31, 2023 | $105.65M | +12.8% |
| Q4 FY2022 | Dec 31, 2022 | $103.06M | +4.3% |
| Q3 FY2022 | Sep 30, 2022 | $101.73M | +5.8% |
| Q2 FY2022 | Jun 30, 2022 | $103.39M | +12.9% |
| Q1 FY2022 | Mar 31, 2022 | $93.69M | +17.9% |
| Q4 FY2021 | Dec 31, 2021 | $98.82M | +15.3% |
| Q3 FY2021 | Sep 30, 2021 | $96.13M | +11.4% |
| Q2 FY2021 | Jun 30, 2021 | $91.59M | +3.4% |
| Q1 FY2021 | Mar 31, 2021 | $79.44M | -14.8% |
| Q4 FY2020 | Dec 31, 2020 | $85.74M | -2.5% |
| Q3 FY2020 | Sep 30, 2020 | $86.33M | +5.9% |
| Q2 FY2020 | Jun 30, 2020 | $88.57M | +22.6% |
| Q1 FY2020 | Mar 31, 2020 | $93.25M | +43.8% |
| Q4 FY2019 | Dec 31, 2019 | $87.90M | +31.5% |
| Q3 FY2019 | Sep 30, 2019 | $81.51M | +26.5% |
| Q2 FY2019 | Jun 30, 2019 | $72.26M | +16.0% |
| Q1 FY2019 | Mar 31, 2019 | $64.83M | +12.4% |
| Q4 FY2018 | Dec 31, 2018 | $66.83M | +25.4% |
| Q3 FY2018 | Sep 30, 2018 | $64.45M | +50.7% |
| Q2 FY2018 | Jun 30, 2018 | $62.31M | +75.2% |
| Q1 FY2018 | Mar 31, 2018 | $57.66M | +108.9% |
| Q4 FY2017 | Dec 31, 2017 | $53.28M | +123.8% |
| Q3 FY2017 | Sep 30, 2017 | $42.76M | +96.8% |
| Q2 FY2017 | Jun 30, 2017 | $35.56M | – |
| Q1 FY2017 | Mar 31, 2017 | $27.60M | – |
| Q4 FY2016 | Dec 31, 2016 | $23.81M | – |
| Q3 FY2016 | Sep 30, 2016 | $21.73M | – |
See a number that looks wrong?